See more : Zensar Technologies Limited (ZENSARTECH.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Quest Diagnostics Incorporated (DGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quest Diagnostics Incorporated, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Ricoh Company, Ltd. (7752.T) Income Statement Analysis – Financial Results
- Cnl Capital E.K.E.S. – AIFM (CNLCAP.AT) Income Statement Analysis – Financial Results
- Heritage Foods Limited (HERITGFOOD.BO) Income Statement Analysis – Financial Results
- WK Group (Holdings) Ltd (2535.HK) Income Statement Analysis – Financial Results
- Doral Group Renewable Energy Resources Ltd (DORL.TA) Income Statement Analysis – Financial Results
Quest Diagnostics Incorporated (DGX)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.questdiagnostics.com
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.25B | 9.88B | 10.79B | 9.44B | 7.73B | 7.53B | 7.71B | 7.52B | 7.49B | 7.44B | 7.15B | 7.38B | 7.51B | 7.37B | 7.46B | 7.25B | 6.70B | 6.27B | 5.50B | 5.13B | 4.74B | 4.11B | 3.63B | 3.42B | 2.21B | 1.46B | 1.53B | 1.62B |
| Cost of Revenue | 6.29B | 6.45B | 6.58B | 5.80B | 5.04B | 4.93B | 4.72B | 4.62B | 4.66B | 4.64B | 4.33B | 4.36B | 4.40B | 4.32B | 4.32B | 4.26B | 3.97B | 3.70B | 3.26B | 2.99B | 2.77B | 2.43B | 2.15B | 1.97B | 1.32B | 813.90M | 875.50M | 1.01B |
| Gross Profit | 2.96B | 3.43B | 4.21B | 3.63B | 2.69B | 2.61B | 2.99B | 2.90B | 2.84B | 2.80B | 2.82B | 3.02B | 3.12B | 3.05B | 3.13B | 2.99B | 2.74B | 2.57B | 2.25B | 2.14B | 1.97B | 1.68B | 1.48B | 1.45B | 886.20M | 644.70M | 653.20M | 605.42M |
| Gross Profit Ratio | 32.00% | 34.74% | 39.02% | 38.50% | 34.80% | 34.59% | 38.79% | 38.58% | 37.85% | 37.63% | 39.46% | 40.88% | 41.48% | 41.41% | 42.03% | 41.29% | 40.79% | 41.04% | 40.82% | 41.66% | 41.57% | 40.79% | 40.69% | 42.49% | 40.19% | 44.20% | 42.73% | 37.46% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.42B | 1.75B | 1.68B | 1.68B | 1.73B | 1.70B | 1.75B | 1.81B | 1.71B | 1.75B | 1.74B | 1.61B | 1.43B | 1.26B | 1.23B | 1.17B | 1.07B | 1.02B | 1.00B | 643.40M | 481.60M | 502.10M | 495.32M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -15.00K | 27.00K | -18.00K | -34.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.62B | 1.87B | 1.73B | 1.55B | 1.46B | 1.42B | 1.75B | 1.68B | 1.68B | 1.73B | 1.70B | 1.75B | 1.81B | 1.71B | 1.75B | 1.74B | 1.61B | 1.43B | 1.26B | 1.23B | 1.17B | 1.07B | 1.02B | 1.00B | 643.40M | 481.60M | 502.10M | 495.32M |
| Other Expenses | 0.00 | 131.00M | 101.00M | 112.00M | 1.00M | -8.00M | 16.00M | -48.00M | -143.00M | 4.00M | 8.00M | 6.70M | 305.79M | 48.47M | 27.04M | 33.98M | 30.87M | 10.91M | 20.49M | 6.70M | 8.20M | 8.37M | 46.11M | 134.30M | 90.80M | 68.80M | 76.40M | 711.38M |
| Operating Expenses | 1.76B | 2.01B | 1.83B | 1.66B | 1.46B | 1.50B | 1.83B | 1.74B | 1.77B | 1.82B | 1.82B | 1.82B | 2.12B | 1.76B | 1.77B | 1.77B | 1.64B | 1.44B | 1.28B | 1.23B | 1.17B | 1.08B | 1.06B | 1.14B | 734.20M | 550.40M | 578.50M | 1.21B |
| Cost & Expenses | 7.94B | 8.46B | 8.41B | 7.47B | 6.50B | 6.43B | 6.54B | 6.36B | 6.43B | 6.45B | 6.15B | 6.18B | 6.52B | 6.07B | 6.10B | 6.03B | 5.61B | 5.14B | 4.54B | 4.23B | 3.94B | 3.52B | 3.22B | 3.10B | 2.05B | 1.36B | 1.45B | 2.22B |
| Interest Income | 11.00M | 10.00M | 1.00M | 3.00M | 5.00M | 2.00M | 2.00M | 1.00M | 1.00M | 3.00M | 3.00M | 3.00M | 2.77M | 1.41M | 2.52M | 5.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 163.00M | 138.00M | 151.00M | 163.00M | 175.00M | 167.00M | 151.00M | 143.00M | 153.00M | 164.00M | 159.00M | 164.70M | 170.60M | 146.10M | 144.10M | 185.48M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 439.00M | 437.00M | 408.00M | 361.00M | 329.00M | 309.00M | 270.00M | 249.00M | 304.00M | 314.00M | 283.00M | 286.60M | 281.10M | 254.00M | 256.70M | 264.60M | 237.88M | 197.40M | 176.12M | 168.73M | 153.90M | 131.39M | 147.73M | 134.30M | 90.80M | 68.80M | 76.40M | 99.10M |
| EBITDA | 1.73B | 1.82B | 3.16B | 2.41B | 1.59B | 1.40B | 1.45B | 1.48B | 1.56B | 1.30B | 1.79B | 1.52B | 1.30B | 1.59B | 1.63B | 1.50B | 1.33B | 1.33B | 1.18B | 1.05B | 950.36M | 723.84M | 559.12M | 452.11M | 242.80M | 163.10M | 151.10M | -502.19M |
| EBITDA Ratio | 18.72% | 18.31% | 29.27% | 25.52% | 20.45% | 18.67% | 18.82% | 18.10% | 20.82% | 17.85% | 18.42% | 20.58% | 17.38% | 21.43% | 22.12% | 21.25% | 19.88% | 21.27% | 21.20% | 21.07% | 19.99% | 17.17% | 15.37% | 13.32% | 14.46% | 11.66% | 13.34% | -31.07% |
| Operating Income | 1.26B | 1.43B | 2.38B | 1.97B | 1.23B | 1.10B | 1.17B | 1.28B | 1.40B | 983.00M | 1.48B | 1.20B | 995.00M | 1.30B | 1.36B | 1.22B | 1.09B | 1.13B | 968.11M | 901.44M | 795.43M | 592.45M | 411.39M | 317.82M | 152.00M | 94.30M | 74.70M | -601.28M |
| Operating Income Ratio | 13.64% | 14.45% | 22.07% | 20.89% | 15.93% | 14.62% | 15.11% | 16.99% | 18.67% | 13.22% | 20.64% | 16.27% | 13.25% | 17.58% | 18.23% | 16.86% | 16.28% | 17.99% | 17.59% | 17.58% | 16.79% | 14.42% | 11.34% | 9.29% | 6.89% | 6.47% | 4.89% | -37.20% |
| Total Other Income/Expenses | -132.00M | -193.00M | 218.00M | -87.00M | -155.00M | -175.00M | -135.00M | -142.00M | -101.00M | -134.00M | 192.00M | -133.00M | -130.77M | -99.28M | -131.18M | -203.42M | -178.93M | -94.73M | -57.66M | -76.55M | -58.66M | -50.07M | -114.80M | -116.84M | -137.60M | -40.40M | -93.80M | -74.92M |
| Income Before Tax | 1.13B | 1.24B | 2.60B | 1.88B | 1.08B | 926.00M | 1.03B | 1.09B | 1.10B | 849.00M | 1.35B | 1.07B | 856.30M | 1.18B | 1.23B | 1.02B | 912.40M | 1.03B | 910.45M | 835.13M | 737.80M | 542.38M | 332.60M | 200.98M | 14.40M | 53.90M | -19.10M | -676.20M |
| Income Before Tax Ratio | 12.21% | 12.50% | 24.09% | 19.96% | 13.93% | 12.30% | 13.36% | 14.45% | 14.72% | 11.42% | 18.86% | 14.47% | 11.40% | 16.07% | 16.47% | 14.06% | 13.61% | 16.48% | 16.54% | 16.29% | 15.57% | 13.20% | 9.17% | 5.87% | 0.65% | 3.70% | -1.25% | -41.84% |
| Income Tax Expense | 248.00M | 264.00M | 597.00M | 460.00M | 247.00M | 182.00M | 241.00M | 429.00M | 373.00M | 262.00M | 500.00M | 401.90M | 349.00M | 425.50M | 460.40M | 386.80M | 358.57M | 407.58M | 364.18M | 335.93M | 301.08M | 220.22M | 148.69M | 96.03M | 15.70M | 27.00M | 3.20M | -50.24M |
| Net Income | 854.00M | 946.00M | 2.00B | 1.43B | 858.00M | 736.00M | 772.00M | 645.00M | 709.00M | 556.00M | 849.00M | 555.70M | 470.60M | 720.90M | 729.10M | 581.50M | 339.94M | 586.42M | 546.28M | 499.20M | 436.72M | 322.15M | 162.30M | 102.05M | -3.40M | 26.90M | -22.30M | -625.96M |
| Net Income Ratio | 9.23% | 9.57% | 18.49% | 15.16% | 11.11% | 9.77% | 10.01% | 8.58% | 9.46% | 7.48% | 11.88% | 7.53% | 6.27% | 9.78% | 9.78% | 8.02% | 5.07% | 9.35% | 9.93% | 9.74% | 9.22% | 7.84% | 4.47% | 2.98% | -0.15% | 1.84% | -1.46% | -38.73% |
| EPS | 7.59 | 8.12 | 15.90 | 10.68 | 6.38 | 5.41 | 5.63 | 4.58 | 4.92 | 3.83 | 5.58 | 3.49 | 2.95 | 4.08 | 3.91 | 2.99 | 1.76 | 2.98 | 2.71 | 2.45 | 2.11 | 1.67 | 0.87 | 0.57 | -0.03 | 0.23 | -0.19 | -5.33 |
| EPS Diluted | 7.52 | 7.98 | 15.53 | 10.52 | 6.29 | 5.29 | 5.50 | 4.51 | 4.87 | 3.81 | 5.54 | 3.46 | 2.92 | 4.05 | 3.87 | 2.97 | 1.74 | 2.94 | 2.66 | 2.35 | 2.02 | 1.62 | 0.83 | 0.54 | -0.03 | 0.22 | -0.19 | -5.33 |
| Weighted Avg Shares Out | 112.00M | 116.00M | 125.00M | 134.00M | 134.00M | 136.00M | 137.00M | 140.00M | 144.00M | 145.00M | 152.00M | 158.60M | 158.70M | 175.70M | 185.90M | 194.30M | 193.24M | 196.99M | 201.83M | 203.75M | 206.97M | 192.91M | 186.56M | 179.04M | 136.00M | 119.56M | 115.84M | 117.45M |
| Weighted Avg Shares Out (Dil) | 113.00M | 118.00M | 128.00M | 136.00M | 136.00M | 139.00M | 140.00M | 142.00M | 145.00M | 145.00M | 153.00M | 160.10M | 160.20M | 177.30M | 187.80M | 196.00M | 195.26M | 199.54M | 205.53M | 212.42M | 216.20M | 199.48M | 195.55M | 188.99M | 136.00M | 120.90M | 116.15M | 117.45M |
Blood-based MRD Test for Cancer Recurrence Can Generate Cost Savings in Colorectal Cancer Treatment, Finds Study in JAMA Health Forum
Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are tested for treatment decisions SECAUCUS, N.J. and BALTIMORE...
Why Is Quest Diagnostics (DGX) Up 3.1% Since Last Earnings Report?
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?
Quest Diagnostics Elects Robert B. Carter, CIO of FedEx Corporation, to Board of Directors
SECAUCUS, N.J. , May 16, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that its Board of Directors has elected Robert (Rob) B.
Quest Diagnostics Declares Quarterly Cash Dividend
SECAUCUS, N.J. , May 15, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on July 22, 2024 to shareholders of record of Quest Diagnostics...
Workforce Drug Test Cheating Surged in 2023, Finds Quest Diagnostics Drug Testing Index Analysis of Nearly 10 Million Drug Tests
Overall Drug Positivity Holds Steady at Historically High Rates while Marijuana Positivity Continued Upward Climb in the General U.S. Workforce Marijuana Positivity in the General U.S. Workforce Escalated in States That Have Legalized Recreational Marijuana as well as in Professional...
Quest Diagnostics to Speak at the 2024 Leerink Partners Healthcare Crossroads Conference
SECAUCUS, N.J. , May 7, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends...
Quest Diagnostics (DGX) Grows in Digital Pathology With New Deal
Quest Diagnostics' (DGX) pathology laboratories nationwide are set to get a boost with PathAI's AISight digital pathology image management system.
Quest Diagnostics Names Murali Balakumar Senior Vice President and Chief Information and Digital Officer
SECAUCUS, N.J. , May 6, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced today that Murali Balakumar, a veteran information technology healthcare business leader, has been named Senior Vice President and Chief Information and...
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
Investors are optimistic about Quest Diagnostics (DGX) on strong legacy business growth.
Quest Diagnostics (DGX) Inks Deal to Acquire PathAI Diagnostics
Quest Diagnostics' (DGX) latest transaction combines its oncology expertise and scale with PathAI's AI and digital pathology innovations.
Source: https://incomestatements.info
Category: Stock Reports